Business
HLS announces that Vascepa® is now reimbursed by the Saskatchewan Drug Plan
HLS announces that Vascepa® is now reimbursed by the Saskatchewan Drug Plan ...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n \n \n \n HLS announces that Vascepa® is now reimbursed by the Saskatchewan Drug Plan\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n Reimbursement coverage for Vascepa in\n \n Canada\n \n is now approximately 70% for publicly covered lives and private coverage is now in excess of 95% for those that are in-label\n \n \n \n \n Public reimbursement for Vascepa is now available in\n \n Ontario\n \n ,\n \n Quebec\n \n ,\n \n Saskatchewan\n \n ,\n \n New Brunswick\n \n ,\n \n Northwest Territories\n \n and for the Non-Insured Health Benefits (NIHB) program for First Nations and Inuit\n \n \n peoples\n \n \n \n \n \n \n TORONTO\n \n \n ,\n \n \n Aug. 2, 2022\n \n \n /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that, effective\n \n August 1, 2022\n \n , it has entered into a Product Listing Agreement (\"PLA\") with the Saskatchewan Drug Plan, for the listing and public reimbursement of Vascepa (icosapent ethyl).\n \n \n Under the terms of the PLA, Vascepa will be reimbursed for the secondary prevention of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with established cardiovascular disease and elevated triglycerides.\n \n \n \"We are pleased to announce the first of the Western provinces to provide public reimbursement coverage for Vascepa as we continue to drive momentum for making the product accessible to a greater number of Canadians,\" said\n \n Gilbert Godin\n \n , CEO of HLS. \"Vascepa is now available for reimbursement for nearly 70% of eligible Canadians on publicly funded plans, and we continue to work with the remaining provinces and territories to secure public plan reimbursement. Cardiovascular disease is the number one killer worldwide and we look forward to bringing this important medication to all Canadians at risk.\"\n \n \n As disclosed previo...